AR100010A1 - EFFECTIVE MARKING OF HUMAN LEUKEMIA USING CELLS DESIGNED WITH AN ANTIGEN CHEMERIC RECEIVER ANTI-CD123 - Google Patents
EFFECTIVE MARKING OF HUMAN LEUKEMIA USING CELLS DESIGNED WITH AN ANTIGEN CHEMERIC RECEIVER ANTI-CD123Info
- Publication number
- AR100010A1 AR100010A1 ARP140100533A ARP140100533A AR100010A1 AR 100010 A1 AR100010 A1 AR 100010A1 AR P140100533 A ARP140100533 A AR P140100533A AR P140100533 A ARP140100533 A AR P140100533A AR 100010 A1 AR100010 A1 AR 100010A1
- Authority
- AR
- Argentina
- Prior art keywords
- chemeric
- antigen
- human leukemia
- car
- leukemia
- Prior art date
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Composiciones y métodos para el tratamiento de la leucemia, por ejemplo, la leucemia mieloide aguda (LMA) y leucemia linfoide aguda de células B (B-LLA). También se refiere a al menos un receptor de antígeno quimérico (CAR) específico a CD123, vectores que comprenden el mismo, y células T recombinantes que comprenden el CAR-CD123. También incluye métodos de administración de una célula T modificada genéticamente que expresa un CAR que comprende un dominio de unión a CD123. También incluye métodos de ablación de la médula ósea para su uso en tratamientos que requieran reacondicionamiento o trasplante de médula ósea.Compositions and methods for the treatment of leukemia, for example, acute myeloid leukemia (AML) and acute lymphoid B-cell leukemia (B-ALL). It also refers to at least one chimeric antigen receptor (CAR) specific to CD123, vectors comprising it, and recombinant T cells comprising CAR-CD123. It also includes methods of administration of a genetically modified T cell expressing a CAR comprising a CD123 binding domain. It also includes bone marrow ablation methods for use in treatments that require reconditioning or bone marrow transplantation.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361767058P | 2013-02-20 | 2013-02-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR100010A1 true AR100010A1 (en) | 2016-09-07 |
Family
ID=58699960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140100533A AR100010A1 (en) | 2013-02-20 | 2014-02-20 | EFFECTIVE MARKING OF HUMAN LEUKEMIA USING CELLS DESIGNED WITH AN ANTIGEN CHEMERIC RECEIVER ANTI-CD123 |
Country Status (1)
Country | Link |
---|---|
AR (1) | AR100010A1 (en) |
-
2014
- 2014-02-20 AR ARP140100533A patent/AR100010A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY35340A (en) | EFFECTIVE MARKING OF HUMAN LEUKEMIA USING CELLS DESIGNED WITH AN ANTIGEN CHEMERIC RECEIVER ANTI-CD123 | |
AU2023200884B2 (en) | Human mesothelin chimeric antigen receptors and uses thereof | |
UY35468A (en) | CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER | |
IL279300A (en) | Glp-1 receptor agonists and uses thereof | |
IL279224A (en) | Glp-1 receptor agonists and uses thereof | |
CO2017001573A2 (en) | Chimeric anti-cd123 antigen receptor | |
IL280718A (en) | T cell receptor constructs and uses thereof | |
MX2017005051A (en) | Heterophasic polypropylene with improved stiffness/impact balance. | |
SA518391159B1 (en) | Affinity-Oligonucleotide Conjugates and Uses Thereof | |
CO2017000510A2 (en) | Car constructs | |
CO2017000507A2 (en) | Chimeric bcma antigen receptor | |
BR112019011450A2 (en) | modified natural killer cells and their use | |
MX2017004539A (en) | Heterophasic polypropylene with improved impact strength/stiffness balance, improved powder flowability, reduced emissions and low shrinkage. | |
CO2017000506A2 (en) | Chimeric cll-1 antigen receptor | |
MX2020001450A (en) | Methods and compositions for reducing immunosupression by tumor cells. | |
MX2016013512A (en) | Systems and methods for concurrent spectrum usage within actively used spectrum. | |
SG10201912494TA (en) | Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use | |
EP3593812A3 (en) | Treatment of cancer using chimeric antigen receptor | |
IL280318A (en) | Resin composition suitable for printing and printing methods | |
SG11202007660UA (en) | Cyclin a1 specific t cell receptors and uses thereof | |
AR112602A1 (en) | ANTI-TrkB ANTIBODIES | |
IT201700037319A1 (en) | NATURAL COMPOSITION FOR USE IN GYNECOLOGY | |
AR100010A1 (en) | EFFECTIVE MARKING OF HUMAN LEUKEMIA USING CELLS DESIGNED WITH AN ANTIGEN CHEMERIC RECEIVER ANTI-CD123 | |
PL3781632T3 (en) | Antifreeze composition | |
GB201817450D0 (en) | Battery composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |